Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
U.S. and U.K. Reach Agreement in Principle on Pharmaceutical Pricing in New Economic Prosperity Deal

The United States and the United Kingdom have reached an agreement in principle on pharmaceutical pricing as part of the new U.S.–U.K. Economic Prosperity Deal, aimed at addressing long-standing pricing...

MRK : 100.89 (-1.35%)
PFE : 25.70 (+0.51%)
GSK : 48.57 (-0.82%)
Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Significant unmet need for patients requires new and novel treatments 1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free...

GSK.LN : 1,827.000 (+0.05%)
GSK : 48.57 (-0.82%)
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)

Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment 1 Data will be...

SPRO : 2.28 (unch)
GSK : 48.57 (-0.82%)
GSK Advances Hepatitis B Treatment with Promising Study Update

GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data,...

GSK : 48.57 (-0.82%)
GSK’s NASH Study Completion: A Potential Game-Changer for Liver Disease Treatment

GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data,...

GSK : 48.57 (-0.82%)
GSK’s RSV Vaccine Study Update: Promising Developments for Older Adults

GlaxoSmithKline ((GSK)) announced an update on their ongoing clinical study.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data,...

GSK : 48.57 (-0.82%)
GlaxoSmithKline (GSK) Receives a Hold from Barclays

In a report released today, Shirley Chen from Barclays maintained a Hold rating on GlaxoSmithKline, with a price target of £14.50. The company’s shares closed yesterday at p1,626.00.Elevate Your Investing...

GSK : 48.57 (-0.82%)
Goldman Sachs Sticks to Their Hold Rating for GlaxoSmithKline (GSK)

In a report released on September 30, Rajan Sharma from Goldman Sachs maintained a Hold rating on GlaxoSmithKline, with a price target of p1,580.00. The company’s shares opened today at p1,675.50.Elevate...

GSK : 48.57 (-0.82%)
New Local Data in GSK and IQVIA's Vaccine Track Supports Smarter Public Health Action at the Community Level

New analysis of metro-area data reveals wide variation in adult vaccination trends across the US and points to opportunities for local action Originally launched in 2022, Vaccine Track...

GSK.LN : 1,827.000 (+0.05%)
GSK : 48.57 (-0.82%)
Nvidia Is Taking Trump’s ‘Stargate’ Idea Global. Should You Buy NVDA Stock Now?

Nvidia will invest 11 billion British pounds in the United Kingdom to shore up the nation’s AI infrastructure.

NVDA : 183.38 (+2.11%)
CRWV : 85.75 (+8.05%)
AZN : 90.03 (-0.90%)
GSK : 48.57 (-0.82%)

Barchart Exclusives

Is This Dividend Stock a Buy for 2026 After Rising 265% in 2025?
Anglogold Ashanti shares have soared this year amid a spike in gold prices. While the shares might take a breather for now, it is a buy-on-the-dip candidate for 2026. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar